Literature DB >> 27109808

The German COPD cohort COSYCONET: Aims, methods and descriptive analysis of the study population at baseline.

Annika Karch1, Claus Vogelmeier2, Tobias Welte3, Robert Bals4, Hans-Ulrich Kauczor5, Jürgen Biederer5, Joachim Heinrich6, Holger Schulz6, Sven Gläser7, Rolf Holle8, Henrik Watz9, Stephanie Korn10, Nina Adaskina1, Frank Biertz1, Charlotte Vogel1, Jørgen Vestbo11, Emiel F M Wouters12, Klaus Friedrich Rabe9, Sandra Söhler13, Armin Koch14, Rudolf A Jörres15.   

Abstract

BACKGROUND: The German COPD cohort study COSYCONET ("COPD and SYstemic consequences-COmorbidities NETwork") investigates the interaction of lung disease, comorbidities and systemic inflammation. Recruitment took place from 2010 to 2013 in 31 study centers. In addition to the baseline visit, follow-up visits are scheduled at 6, 18, 36 and 54 months after baseline. The study also comprises a biobank, image bank, and includes health economic data. Here we describe the study design of COSYCONET and present baseline data of our COPD cohort.
METHODS: Inclusion criteria were broad in order to cover a wide range of patterns of the disease. In each visit, patients undergo a large panel of assessments including e.g. clinical history, spirometry, body plethysmography, diffusing capacity, blood samples, 6-min walk-distance, electrocardiogram and echocardiography. Chest CTs are collected if available and CTs and MRIs are performed in a subcohort. Data are entered into eCRFs and subjected to several stages of quality control.
RESULTS: Overall, 2741 subjects with a clinical diagnosis of COPD were included (59% male; mean age 65 ± 8.6 years (range 40-90)). Of these, 8/35/32/9% presented with GOLD stages I-IV; 16% were uncategorized, including the former GOLD-0 category. 24% were active smokers, 68% ex-smokers and 8% never-smokers. Data completeness was 96% for the baseline items.
CONCLUSION: The German COPD cohort comprises patients with advanced and less advanced COPD. This is particularly useful for studying the time course of COPD in relation to comorbidities. Baseline data indicate that COSYCONET offers the opportunity to investigate our research questions in a large-scale, high-quality dataset.
Copyright © 2016 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  COPD; Cohort; Comorbidity; Study design; Systemic inflammation

Mesh:

Year:  2016        PMID: 27109808     DOI: 10.1016/j.rmed.2016.03.008

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  44 in total

1.  [The lung in systemic diseases : Between holistic and individualized medicine-a challenge for internal medicine].

Authors:  T Welte; C Vogelmeier; W Hiddemann; E Märker-Hermann
Journal:  Internist (Berl)       Date:  2018-09       Impact factor: 0.743

2.  [Cardiovascular outcome in patients with COPD : Study to Understand Mortality and Morbidity (SUMMIT)].

Authors:  T Welte; S Nitschmann
Journal:  Internist (Berl)       Date:  2016-11       Impact factor: 0.743

Review 3.  Bridging gaps between images and data: a systematic update on imaging biobanks.

Authors:  Michela Gabelloni; Lorenzo Faggioni; Rita Borgheresi; Giuliana Restante; Jorge Shortrede; Lorenzo Tumminello; Camilla Scapicchio; Francesca Coppola; Dania Cioni; Ignacio Gómez-Rico; Luis Martí-Bonmatí; Emanuele Neri
Journal:  Eur Radiol       Date:  2022-01-10       Impact factor: 5.315

4.  Impact of the COVID-19 pandemic on the behaviour and health status of patients with COPD: results from the German COPD cohort COSYCONET.

Authors:  Kathrin Kahnert; Johanna I Lutter; Tobias Welte; Peter Alter; Jürgen Behr; Felix Herth; Hans-Ulrich Kauczor; Sandra Söhler; Michael Pfeifer; Henrik Watz; Claus F Vogelmeier; Robert Bals; Rudolf A Jörres; Franziska C Trudzinski
Journal:  ERJ Open Res       Date:  2021-08-23

5.  Sex-specific associations of comorbidome and pulmorbidome with mortality in chronic obstructive pulmonary disease: results from COSYCONET.

Authors:  Franziska C Trudzinski; Rudolf A Jörres; Peter Alter; Julia Walter; Henrik Watz; Andrea Koch; Matthias John; Marek Lommatzsch; Claus F Vogelmeier; Hans-Ulrich Kauczor; Tobias Welte; Jürgen Behr; Amanda Tufman; Robert Bals; Felix J F Herth; Kathrin Kahnert
Journal:  Sci Rep       Date:  2022-05-24       Impact factor: 4.996

6.  Differences in the Measurement of Functional Residual Capacity Between Body Plethysmographs of Two Manufacturers.

Authors:  Peter Alter; Jan Orszag; Emiel F M Wouters; Claus F Vogelmeier; Rudolf A Jörres
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2022-06-24

7.  Medical Treatment of COPD.

Authors:  Jana Graf; Rudolf A Jörres; Tanja Lucke; Dennis Nowak; Claus F Vogelmeier; Joachim H Ficker
Journal:  Dtsch Arztebl Int       Date:  2018-09-14       Impact factor: 5.594

8.  NADPH oxidase subunit NOXO1 is a target for emphysema treatment in COPD.

Authors:  Michael Seimetz; Natascha Sommer; Mariola Bednorz; Oleg Pak; Christine Veith; Stefan Hadzic; Marija Gredic; Nirmal Parajuli; Baktybek Kojonazarov; Simone Kraut; Jochen Wilhelm; Fenja Knoepp; Ingrid Henneke; Alexandra Pichl; Zeki I Kanbagli; Susan Scheibe; Athanasios Fysikopoulos; Cheng-Yu Wu; Walter Klepetko; Peter Jaksch; Christina Eichstaedt; Ekkehard Grünig; Katrin Hinderhofer; Miklós Geiszt; Niklas Müller; Flavia Rezende; Giulia Buchmann; Ilka Wittig; Matthias Hecker; Andreas Hecker; Winfried Padberg; Peter Dorfmüller; Stefan Gattenlöhner; Claus F Vogelmeier; Andreas Günther; Srikanth Karnati; Eveline Baumgart-Vogt; Ralph T Schermuly; Hossein A Ghofrani; Werner Seeger; Katrin Schröder; Friedrich Grimminger; Ralf P Brandes; Norbert Weissmann
Journal:  Nat Metab       Date:  2020-06-08

9.  Assessing health-related quality of life in COPD: comparing generic and disease-specific instruments with focus on comorbidities.

Authors:  Margarethe E Wacker; Rudolf A Jörres; Annika Karch; Sarah Wilke; Joachim Heinrich; Stefan Karrasch; Armin Koch; Holger Schulz; Henrik Watz; Reiner Leidl; Claus Vogelmeier; Rolf Holle
Journal:  BMC Pulm Med       Date:  2016-05-10       Impact factor: 3.317

10.  Relative impact of COPD and comorbidities on generic health-related quality of life: a pooled analysis of the COSYCONET patient cohort and control subjects from the KORA and SHIP studies.

Authors:  Margarethe E Wacker; Rudolf A Jörres; Annika Karch; Armin Koch; Joachim Heinrich; Stefan Karrasch; Holger Schulz; Annette Peters; Sven Gläser; Ralf Ewert; Sebastian E Baumeister; Claus Vogelmeier; Reiner Leidl; Rolf Holle
Journal:  Respir Res       Date:  2016-07-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.